Skip directly to site content Skip directly to page options Skip directly to A-Z link


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
															Search

		Submit


Vaccine Safety


Section Navigation
			
			CDC Home


Facebook
        Twitter
        LinkedIn
        Syndicate





MMRV Vaccine Safety Studies										Related Pages
										Results from Studies Before MMRV Vaccine Was Licensed
Here are key findings from CDC’s Vaccine Safety Datalink (VSD) studies of MMRV vaccine (before it was licensed) among children aged 12-23 months:
kid looking at the camera
Two adverse events occurred more frequently during the 42 days after the first dose of MMRV vaccine compared with separate injections of MMR and varicella vaccines—a  fever of 102° F or higher and rash. Most of the risk for fever and rash was in the 5-12 days after vaccination.  These conditions typically resolved on their own.
Soreness at the injection site was reported less often after MMRV vaccine than after MMR and varicella vaccines given in separate shots at the same visit.
The rates of adverse events after MMRV vaccination were:
Soreness at injection site: 1 child out of 5;
Fever: 1 child out of 5; and
Rash: 1 child out of 20.
The rates of adverse events for MMR and varicella vaccines administered at the same visit were:
Soreness at injection site: 1 child out of 4;
Fever: 1 child out of 7; and
Rash: 1 child out of 25.Because these studies showed an increased risk for fever after MMRV vaccination, compared with vaccination with MMR and varicella vaccines in separate shots at the same visit, there was concern about a potential increased risk for febrile seizures (seizures triggered by a rising or dropping fever) after MMRV vaccination. As part of routine monitoring of vaccine safety for all new vaccines, CDC conducted studies of the safety of MMRV vaccine. In these studies, CDC analyzed data reported to the Vaccine Safety Datalink (VSD) regarding MMRV vaccine given to children aged 12-23 months, the age when the first dose of MMRV or MMR and varicella vaccines is recommended. The study assessed the rate of several medical events after MMRV vaccination, including febrile seizures.
Top of PageResults from Studies After MMRV Vaccine Was Licensed
The following findings are from CDC’s Vaccine Safety Datalink (VSD) study of the safety of MMRV vaccine (after it was licensed) among children aged 12-23 months:
7-10 days after the first dose of vaccination, the rate of febrile seizures was about 2 times higher among children who received MMRV vaccine (8.5 per 10,000 children vaccinated) than among children who received measles, mumps, and rubella (MMR) and varicella vaccines separately at the same visit (4.2 per 10,000 children vaccinated), mainly before MMRV vaccine became available.
7-10 days after vaccination, about one additional febrile seizure would be expected to occur among every 2,300 children vaccinated with first-dose MMRV vaccine compared with children vaccinated with the first doses of MMR and varicella shots at the same visit.Merck, the manufacturer of the MMRV vaccine, also sponsored an observational study (after MMRV vaccine was licensed) of febrile seizures after the first dose of MMRV vaccine was given to children aged 12-23 months. Here are some key findings from that study:
The rate of febrile seizures 5-12 days after first dose of vaccination was 7.0 per 10,000 children who received MMRV vaccine compared with a rate of 3.2 per 10,000 children who received measles, mumps, rubella (MMR) and varicella vaccines separately at the same visit (3.2 is the rate before MMRV vaccine became available).
5-12 days after vaccination, about one additional febrile seizure would be expected to occur among every 2,600 children vaccinated with the first dose of MMRV vaccine compared with children vaccinated with the first doses of MMR and varicella vaccines administered at the same visit.These findings and other relevant data were presented to the Advisory Committee on Immunization Practices (ACIP). In May 2010, CDC released new recommendations on the use of MMRV vaccine.
To help parents and healthcare providers better understand the ACIP recommendations, risks and benefits of MMRV vaccine, and febrile seizures, the following information is available:
For Parents and Caregivers: Fact Sheet on Measles, Mumps, Rubella, and Varicella
For Parents and Caregivers: Frequently Asked Questions on MMRV Vaccines
For Providers: Fact Sheet for Providers on MMR & Varicella Vaccines or MMRV Vaccine
For Providers: Frequently Asked Questions on MMRV Vaccines
Frequently Asked Questions about Febrile Seizures Following Childhood Vaccinations
Information on the VSD MMRV Vaccine Safety Study
Merck Package Insert for ProQuad (MMRV vaccine) [PDF – 25 pages]external iconTop of PageRelated Scientific Articles
Jacobsen SJ, Ackerson BK, Sy LS, Tran TN, Jones TL, Yao JF, Xie F, Cheetham TC, Saddier P. Observational safety study of febrile convulsion following first dose MMRV vaccination in a managed care settingexternal icon. *Vaccine* 2009 Jul 23;27(34):4656-61.
Klein NP, Fireman B, Yih WK, et al. Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures. *Pediatrics* 2010. In press.
Top of Page
							
					
						Page last reviewed:  June 4, 2020					Content source: 	Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), Division of Healthcare Quality Promotion (DHQP) homeVaccine Safety
Safety Information by Vaccineplus icon
Chickenpox (Varicella) Vaccines
COVID-19 Vaccines
Diphtheria, Tetanus, and Pertussis Vaccines
Haemophilus influenzae type b (Hib) Vaccines
Hepatitis A Vaccines
Hepatitis B Vaccines
Human Papillomavirus (HPV) Vaccineplus icon
Questions about HPV Vaccine Safety
Influenza (Flu) Vaccines
Measles, Mumps, Rubella (MMR) Vaccinesplus icon
MMR Safety Studies
Measles, Mumps, Rubella, Varicella (MMRV) Vaccinesplus icon
VSD MMRV Safety Study
MMRV Safety Studies
MMRV and Febrile Seizures
Meningococcal Vaccines
Mpox Vaccines
Pneumococcal Vaccines
Polio Vaccine
Respiratory Syncytial Virus (RSV) Vaccine
Rotavirus Vaccine
Shingles (Herpes Zoster) Vaccines
Smallpox Vaccines
Questions and Concernsplus icon
Adjuvants
Autismplus icon
CDC Statement: 2004 Pediatrics Paper on MMR and Autism
Fainting after Vaccination
Febrile Seizures
Guillain-Barre Syndrome
Multiple Vaccinations at Once
Sudden Infant Death Syndrome (SIDS)
Thimerosalplus icon
CDC Study (2010 ) on Thimerosal and Risk of Autism
Thimerosal FAQs
Related Scientific Articles
Infant and Environmental Exposures to Thimerosal 2007 Study
Timeline: Thimerosal in Vaccines
Vaccines During Pregnancy FAQs
FAQs about Vaccine Recalls
Historical Vaccine Safety Concernsplus icon
GBS and Menactra Vaccine FAQs
Gardasil Vaccine Recall (2013) FAQs
Hep B and Multiple Sclerosis FAQs
Hib Vaccine Recall (2007) Summary
Narcolepsy Following Pandemrix Influenza Vaccination in Europe
Information for Healthcare Providersplus icon
Talking to Patients About Vaccine Safety
Reporting Adverse Events
Resources for Healthcare Providers
Information for Parents and Caregiversplus icon
Vaccine Safety FAQs
Researchplus icon
Publications
Partner Reports on Vaccine Safety
ISO Scientific Agenda
Ensuring Safetyplus icon
Overview, History, and How It Works
Side Effects and Adverse Events
Vaccine Safety Monitoringplus icon
Vaccine Adverse Event Reporting System (VAERS)
CISAplus icon
CISA Resources for Healthcare Professionals
Evaluation
Clinical Research Studies
Historical Background 2001-12
Publications
Technical Reports
Vaccine Safety Datalink (VSD)plus icon
Accessing Data from Vaccine Safety Datalink
Data Sharing Guidelines
Vaccine Safety Datalink Publications
V-safe
V-safe Publications
Emergency Preparedness
Vaccine Safety Partners
About ISO To receive email updates about this page, enter your email address: Email Address			What's this?				Submit


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue